Adenoid hypertrophy. Hypertrophy of adenoids
Conditions
Interventions
Intervention 1: Control group or fluticasone: A group of patients who use fluticasone nasal spray twice a day at a dose of 50ug for 6 weeks. Then clinical symptoms and lateral neck radiography and aud
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
4 Years to 12 Years
Inclusion criteria
Inclusion criteria: Age 4 to 12 years Adenoid obstruction of at least 50% of the nasopharynx on lateral neck radiography with one of the symptoms of chronic nasal obstruction consistent with adenoid hypertrophy (mouth breathing, nasal discharge, snoring, chronic cough, nasal speech) Grade one or two palatine tonsils Absence of chronic tonsillitis Not having peritonsillar abscesses more than twice a year No history of previous adenoid surgery or tonsillectomy There are no contraindications to the use of topical corticosteroid in the form of a nasal spray. Patient and parent consent to participate in the study No upper respiratory infection in the past 2 weeks Absence of anatomical sinus abnormalities or diseases, craniofacial abnormalities such as cleft lip and palate, genetic diseases (e.g., Down syndrome), neurological or cardiovascular diseases, history of asthma, hypersensitivity to study drugs No steroid or antibiotic treatment, topical or systemic, in the past 4 weeks
Exclusion criteria
Exclusion criteria: Grade three or four palatine tonsils Having peritonsillar abscesses more than twice a year Upper respiratory infection in the past 2 weeks History of previous adenoid surgery or tonsillectomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adenoid size. Timepoint: At the beginning of the study (before the start of the intervention), 6 weeks after taking the drug. Method of measurement: Adenoid to choanae size ratio on lateral neck radiograph.;Nasal speech. Timepoint: At the beginning of the study (before the intervention), 6 weeks after taking the drug, 6 weeks after stopping the drug. Method of measurement: Clinical symptom questionnaire.;Mouth breathing. Timepoint: At the beginning of the study (before the intervention), 6 weeks after taking the drug, 6 weeks after stopping the drug. Method of measurement: Clinical symptom questionnaire.;Snoring. Timepoint: At the beginning of the study (before the intervention), 6 weeks after taking the drug, 6 weeks after stopping the drug. Method of measurement: SNORING SCALE SCORE -Cambridge University.;Chronic cough. Timepoint: At the beginning of the study (before the intervention), 6 weeks after taking the drug, 6 weeks after stopping the drug. Method of measurement: Clinical symptom questionnaire.;Rhinorrhea. Timepoint: At the beginning of the study (before the intervention), 6 weeks after taking the drug, 6 weeks after stopping the drug. Method of measurement: Clinical symptom questionnaire.;Air bone gap in audiometry. Timepoint: At the beginning of the study (before the intervention), 6 weeks after taking the drug. Method of measurement: Audiometry.;Tympanometry. Timepoint: At the beginning of the study (before the start of the intervention), 6 weeks after taking the drug. Method of measurement: Tympanometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZohreh Ajalloueyan
Bagheiat-allah University of Medical Sciences
Outcome results
None listed